Evidence map›Paper›PMID 42634326›Full record

ArticleRenal failure2026

Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study.

Juan Pei, Xuejuan Sun, Xiuhua Xu, Peijin Bai, Ruihong Huang, Jun Zhang, Xing Chen, Lijing Yao, Leping Shao, Yinan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Juan PeiDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xuejuan SunDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiuhua XuDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Peijin BaiDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Ruihong HuangDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jun ZhangDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xing ChenDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Lijing YaoDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Leping ShaoDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yinan LiDepartment of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and a leading cause of end-stage renal disease. Finerenone reduces proteinuria in diabetic kidney disease, but evidence in IgAN remains limited. This single-center retrospective study included adults with biopsy-proven IgAN who initiated finerenone therapy between January 2023 and December 2025 and were followed for at least 90 days. The primary outcomes included changes in 24-hour urinary protein (24hUP) and estimated glomerular filtration rate (eGFR), and subgroup analysis was performed in patients not receiving immunosuppressive therapy. A total of 52 patients were included (mean age 40.6 ± 9.7 years; 71.2% female). Median 24hUP decreased from 750.0 mg/24h at baseline to 496.0 mg/24h at Month 12 (median reduction 29.7%,

Indexed as

Glomerulonephritis, IGAMineralocorticoid Receptor AntagonistsProteinuriaAdultFemaleGlomerular Filtration RateHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeMineralocorticoid Receptor AntagonistsFinerenoneglomerular filtration rateIgA nephropathymineralocorticoid receptor antagonistproteinuria

Identifiers

PMID42634326
PMCPMC13508533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.